The market expects 10x Genomics (TXG) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...

We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

Across the recent three months, 6 analysts have shared their insights on 10x Genomics (NASDAQ:TXG), expressing a variety of opinions spanning from bullish to bearish. The table below summarizes ...

10x Genomics (NASDAQ:TXG – Get Free Report)‘s stock had its “sell (e+)” rating reiterated by analysts at Weiss Ratings in a research note issued to investors on Saturday,Weiss Ratings reports.

Nisa Investment Advisors LLC acquired a new position in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) in the 4th quarter, HoldingsChannel reports. The firm acquired 16,500 shares of the ...

In a report released today, Michael Ryskin from Bank of America Securities maintained a Hold rating on 10x Genomics (TXG – Research Report).

Data is delayed at least 15 minutes. Nasdaq.com will report pre-market and after hours trades. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the following day.

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets.

Cathie Wood's ARK ETFs have disclosed their daily trades for Friday, February 7th, 2025, with significant activity across a variety of sectors. ARK's largest transaction for the day involved ...

10x Genomics (NASDAQ:TXG – Get Free Report) had its price objective lowered by research analysts at Morgan Stanley from $30.00 to $28.00 in a note issued to investors on Monday,Benzinga reports.